Executive record

James Robinson

Director at Eledon Pharmaceuticals, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:james-robinsonVersion: public-0As of: 2026-09-28

Not yet claimed9 published Claims3 sources
  • Director

Key Claims

Biography

James Robinson is CEO and Director of A2 Biotherapeutics, a clinical stage private company focused on cell therapy for cancer, since April 2024. He previously served as CEO of Urovant Sciences from 2020-2023, guiding the company through its first product launch and acquisition by Sumitomo Dainippon Pharma. He has extensive senior leadership experience in life sciences with over 12 years at Astellas Pharma.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Chief Executive Officer · Organization not publishedELDN DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ELDN DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 15, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Audit, Compensation · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at A2 Biotherapeutics, Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Executive Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Eledon Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Eledon Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026